drugset / Trial / NCT05767723

Platelet Sub-study of the Neomindset Trial

NCT05767723

Phase 4 Active not recruiting 48 enrolled Hospital Israelita Albert Einstein
RandomizedParallel-groupSingle-blindDiagnostic

Summary

The general purpose of the Neomindset trial is to evaluate the non-inferiority hypothesis for ischemic events and the superiority hypothesis for bleeding events resulting from platelet P2Y12 receptor inhibitors given as monotherapy in comparison with conventional dual antiplatelet therapy in acute coronary syndrome patients treated with percutaneous coronary intervention. The platelet sub-study will be conducted at the Hospital Israelita Albert Einstein. This sub-study will recruit randomized patients from the Neomindset trial to evaluate platelet function after at least 30 days of study treatment with either P2Y12 inhibitor monotherapy or dual antiplatelet therapy.

Timeline

Start
2023-02-06
Primary completion
2025-05-30
Completion
2025-06-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aspirin Small molecule 100 mg
Comparator Prasugrel Small molecule 10 mg
Comparator Ticagrelor Small molecule 90 mg